Abbott Lab’s Niaspan beat out Merck’s Zetia (ezetimibe) in concomitant therapy with statins when looking at atherosclerosis. The study, which was presented at the American Heart Association scientific meeting in Orlando, was tiny in scope with only 208 patients participating.
This is bad news for Merck. The company’s Zetia has had negative news in previous trials. Also, sales of Vytorin have stumbled in recent years.
This is bad news for Merck. The company’s Zetia has had negative news in previous trials. Also, sales of Vytorin have stumbled in recent years.